Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia

2.

Burger

JA

,

Tedeschi

A

,

Barr

PM

, et al.

Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

.

N Engl J Med

.

2015

;

373

(

25

):

2425

-

2437

.

3.

Al-Sawaf

O

,

Zhang

C

,

Tandon

M

, et al.

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

.

Lancet Oncol

.

2020

;

21

(

9

):

1188

-

1200

.

4.

Al-Sawaf

O

,

Zhang

C

,

Lu

T

, et al.

Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study

.

J Clin Oncol

.

2021

;

39

(

36

):

4049

-

4060

.

5.

Munir

T

,

Cairns

DA

,

Bloor

A

, et al.

Chronic lymphocytic leukemia therapy guided by measurable residual disease

.

N Engl J Med

.

2024

;

390

(

4

):

326

-

337

.

6.

Hallek

M

,

Al-Sawaf

O

.

Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures

.

Am J Hematol

.

2021

;

96

(

12

):

1679

-

1705

.

7.

Furstenau

M

,

De Silva

N

,

Eichhorst

B

,

Hallek

M

.

Minimal residual disease assessment in CLL: ready for use in clinical routine?

.

Hemasphere

.

2019

;

3

(

5

):

e287

.

8.

Al-Sawaf

O

,

Zhang

C

,

Jin

HY

, et al.

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

.

Nat Commun

.

2023

;

14

(

1

):

2147

.

9.

Seymour

JF

,

Kipps

TJ

,

Eichhorst

BF

, et al.

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

.

Blood

.

2022

;

140

(

8

):

839

-

850

.

10.

Thompson

MC

,

Harrup

RA

,

Coombs

CC

, et al.

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

.

Blood Adv

.

2022

;

6

(

15

):

4553

-

4557

.

11.

Aronson

JH

,

Skånland

SS

,

Roeker

LE

,

Thompson

MC

,

Mato

AR

.

Approach to a patient with “double refractory” chronic lymphocytic leukemia: “double, double toil and trouble” (Shakespeare)

.

Am J Hematol

.

2022

;

97

(

suppl 2

):

S19

-

S25

.

12.

Kater

AP

,

Owen

C

,

Moreno

C

, et al.

Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities

.

NEJM Evid

.

2022

;

1

(

7

):

EVIDoa2200006

.

13.

Tam

CS

,

Allan

JN

,

Siddiqi

T

, et al.

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

.

Blood

.

2022

;

139

(

22

):

3278

-

3289

.

14.

Huber

H

,

Tausch

E

,

Schneider

C

, et al.

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut

.

Blood

.

2023

;

142

(

11

):

961

-

972

.

15.

Lew

TE

,

Lin

VS

,

Cliff

ER

, et al.

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition

.

Blood Adv

.

2021

;

5

(

20

):

4054

-

4058

.

16.

Hampel

PJ

,

Rabe

KG

,

Call

TG

, et al.

Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia

.

Br J Haematol

.

2022

;

199

(

2

):

239

-

244

.

17.

Samples

L

,

Ujjani

CS

,

Khajaviyan

S

, et al.

Clinical outcomes in patients treated with both covalent Btkis and venetoclax and the significance of “double-refractory” status in patients with CLL/SLL

.

Blood

.

2023

;

142

(

suppl1

):

4650

.

18.

Hyak

JM

,

Huang

Y

,

Rogers

KA

, et al.

Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes

.

Blood Adv

.

2022

;

6

(

17

):

5124

-

5127

.

19.

Byrd

JC

,

Hillmen

P

,

Ghia

P

, et al.

Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial

.

J Clin Oncol

.

2021

;

39

(

31

):

3441

-

3452

.

20.

Awan

FT

,

Schuh

A

,

Brown

JR

, et al.

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib

.

Blood Adv

.

2019

;

3

(

9

):

1553

-

1562

.

21.

DiPippo

AJ

,

McGhie

A

,

Lee

J

, et al.

Tolerability of acalabrutinib after prior ibrutinib treatment in patients with CLL: experience of a Tertiary Cancer Care Center

.

Blood

.

2022

;

140

(

suppl 1

):

4153

-

4155

.

22.

Brown

JR

,

Eichhorst

B

,

Hillmen

P

, et al.

Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia

.

N Engl J Med

.

2023

;

388

(

4

):

319

-

332

.

23.

Hallek

M

,

Fischer

K

,

Fingerle-Rowson

G

, et al.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

.

Lancet

.

2010

;

376

(

9747

):

1164

-

1174

.

24.

Fischer

K

,

Cramer

P

,

Busch

R

, et al.

Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

.

J Clin Oncol

.

2012

;

30

(

26

):

3209

-

3216

.

25.

Mato

AR

,

Roeker

LE

,

Jacobs

R

, et al.

Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy

.

Clin Cancer Res

.

2020

;

26

(

14

):

3589

-

3596

.

26.

Furman

RR

,

Sharman

JP

,

Coutre

SE

, et al.

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

.

N Engl J Med

.

2014

;

370

(

11

):

997

-

1007

.

27.

Flinn

IW

,

Hillmen

P

,

Montillo

M

, et al.

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

.

Blood

.

2018

;

132

(

23

):

2446

-

2455

.

28.

Hanlon

A

,

Brander

DM

.

Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors

.

Hematology

.

2020

;

2020

(

1

):

346

-

356

.

29.

Woyach

JA

,

Ruppert

AS

,

Guinn

D

, et al.

BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia

.

J Clin Oncol

.

2017

;

35

(

13

):

1437

-

1443

.

30.

Woyach

JA

,

Furman

RR

,

Liu

T-M

, et al.

Resistance mechanisms for the bruton's tyrosine kinase inhibitor ibrutinib

.

N Engl J Med

.

2014

;

370

(

24

):

2286

-

2294

.

31.

Mato

AR

,

Woyach

JA

,

Brown

JR

, et al.

Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia

.

N Engl J Med

.

2023

;

389

(

1

):

33

-

44

.

32.

Wang

E

,

Mi

X

,

Thompson

MC

, et al.

Mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors

.

N Engl J Med

.

2022

;

386

(

8

):

735

-

743

.

33.

Dobrovolsky

D

,

Wang

ES

,

Morrow

S

, et al.

Bruton tyrosine kinase degradation as a therapeutic strategy for cancer

.

Blood

.

2019

;

133

(

9

):

952

-

961

.

34.

Mato

AR

,

Wierda

WG

,

Ai

WZ

, et al.

NX-2127-001, a first-in-human trial of NX-2127, a Bruton's tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies

.

Blood

.

2022

;

140

(

suppl 1

):

2329

-

2332

.

35.

Thijssen

R

,

Tian

L

,

Anderson

MA

, et al.

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy

.

Blood

.

2022

;

140

(

20

):

2127

-

2141

.

36.

Thomalla

D

,

Beckmann

L

,

Grimm

C

, et al.

Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies

.

Blood

.

2022

;

140

(

20

):

2113

-

2126

.

37.

Jayappa

KD

,

Gordon

VL

,

Morris

CG

, et al.

Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL

.

Blood Adv

.

2021

;

5

(

17

):

3497

-

3510

.

38.

Jayappa

KD

,

Portell

CA

,

Gordon

VL

, et al.

Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL

.

Blood Adv

.

2017

;

1

(

14

):

933

-

946

.

39.

Park

E

,

Chen

J

,

Moore

A

, et al.

Stromal cell protein kinase C-beta inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance

.

Sci Transl Med

.

2020

;

12

(

526

):

eaax9340

.

40.

Hormi

M

,

Birsen

R

,

Belhadj

M

, et al.

Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML

.

Eur J Haematol

.

2020

;

105

(

5

):

588

-

596

.

41.

Roberts

AW

,

Wei

AH

,

Huang

DCS

.

BCL2 and MCL1 inhibitors for hematologic malignancies

.

Blood

.

2021

;

138

(

13

):

1120

-

1136

.

42.

de Vos

S

,

Leonard

JP

,

Friedberg

JW

, et al.

Safety and efficacy of navitoclax, a BCL-2 and BCL-X(L) inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study

.

Leuk Lymphoma

.

2021

;

62

(

4

):

810

-

818

.

43.

Kipps

TJ

.

ROR1: an orphan becomes apparent

.

Blood

.

2022

;

140

(

14

):

1583

-

1591

.

44.

Ghia

EM

,

Rassenti

LZ

,

Choi

MY

, et al.

High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia

.

Leukemia

.

2022

;

36

(

6

):

1609

-

1618

.

45.

Cui

B

,

Ghia

EM

,

Chen

L

, et al.

High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia

.

Blood

.

2016

;

128

(

25

):

2931

-

2940

.

46.

Lee

HJ

,

Choi

MY

,

Siddiqi

T

, et al.

Phase 1/2 study of zilovertamab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)

.

J Clin Oncol

.

2022

;

40

(

16 suppl

):

7520

.

47.

Townsend

W

,

Leong

S

,

Shah

M

, et al.

Time limited exposure to a ROR1 targeting bispecific T cell engager (NVG-111) leads to durable responses in subjects with relapsed refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)

.

Blood

.

2023

;

142

(

suppl 1

):

329

.

48.

Vom Stein

AF

,

Hallek

M

,

Nguyen

PH

.

Role of the tumor microenvironment in CLL pathogenesis

.

Semin Hematol

.

2024

;

61

(

3

):

142

-

154

.

49.

Vlachonikola

E

,

Stamatopoulos

K

,

Chatzidimitriou

A

.

T cells in chronic lymphocytic leukemia: a two-edged sword

.

Front Immunol

.

2020

;

11

:

612244

.

50.

Purroy

N

,

Tong

YE

,

Lemvigh

CK

, et al.

Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib

.

Blood

.

2022

;

139

(

14

):

2252

-

2256

.

51.

Riches

JC

,

Davies

JK

,

McClanahan

F

, et al.

T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production

.

Blood

.

2013

;

121

(

9

):

1612

-

1621

.

52.

Qorraj

M

,

Bruns

H

,

Böttcher

M

, et al.

The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia

.

Leukemia

.

2017

;

31

(

2

):

470

-

478

.

53.

Carlino

MS

,

Larkin

J

,

Long

GV

.

Immune checkpoint inhibitors in melanoma

.

Lancet

.

2021

;

398

(

10304

):

1002

-

1014

.

54.

Reck

M

,

Rodríguez-Abreu

D

,

Robinson

AG

, et al.

Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer

.

N Engl J Med

.

2016

;

375

(

19

):

1823

-

1833

.

55.

McClanahan

F

,

Hanna

B

,

Miller

S

, et al.

PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia

.

Blood

.

2015

;

126

(

2

):

203

-

211

.

56.

Ding

W

,

LaPlant

BR

,

Call

TG

, et al.

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

.

Blood

.

2017

;

129

(

26

):

3419

-

3427

.

57.

Goedhart

NB

,

Simon-Molas

H

,

Montironi

C

, et al.

Multifactorial basis of T cell dysfunction in CLL: disrupted mitochondrial metabolism induces T cell senescence

.

Blood

.

2023

;

142

(

suppl 1

):

4629

.

58.

Martens

AWJ

,

Kavazovic

I

,

Krapic

M

, et al.

Chronic lymphocytic leukemia presence impairs antigen-specific CD8(+) T-cell responses through epigenetic reprogramming towards short-lived effectors

.

Leukemia

.

2023

;

37

(

3

):

606

-

616

.

59.

van Bruggen

JAC

,

Martens

AWJ

,

Fraietta

JA

, et al.

Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy

.

Blood

.

2019

;

134

(

1

):

44

-

58

.

60.

Fraietta

JA

,

Lacey

SF

,

Orlando

EJ

, et al.

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

.

Nat Med

.

2018

;

24

(

5

):

563

-

571

.

61.

Montironi

C

,

Jacobs

CF

,

Cretenet

G

, et al.

T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia

.

Blood Adv

.

2023

;

7

(

21

):

6540

-

6552

.

62.

Hanna

BS

,

Yazdanparast

H

,

Demerdash

Y

, et al.

Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice

.

Haematologica

.

2021

;

106

(

4

):

968

-

977

.

63.

Younes

A

,

Brody

J

,

Carpio

C

, et al.

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study

.

Lancet Haematol

.

2019

;

6

(

2

):

e67

-

e78

.

64.

Jain

N

,

Senapati

J

,

Thakral

B

, et al.

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

.

Blood Adv

.

2023

;

7

(

10

):

1958

-

1966

.

65.

Al-Sawaf

O

,

Ligtvoet

R

,

Robrecht

S

, et al.

Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial

.

Nat Med

.

2024

;

30

(

1

):

240

-

248

.

66.

Li

J

,

Xu

J

,

Li

Z

.

Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade

.

Transl Oncol

.

2021

;

14

(

8

):

101116

.

67.

Kohlhapp

FJ

,

Haribhai

D

,

Mathew

R

, et al.

Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade

.

Cancer Discov

.

2021

;

11

(

1

):

68

-

79

.

68.

Jain

N

,

Ferrajoli

A

,

Yilmaz

M

, et al.

Venetoclax, obinutuzumab and atezolizumab (PD-L1 checkpoint inhibitor) for first-line treatment for patients with chronic lymphocytic leukemia (CLL)

.

Blood

.

2021

;

138

(

suppl 1

):

2626

.

69.

Dickinson

MJ

,

Carlo-Stella

C

,

Morschhauser

F

, et al.

Glofitamab for relapsed or refractory diffuse large B-cell lymphoma

.

N Engl J Med

.

2022

;

387

(

24

):

2220

-

2231

.

70.

Hutchings

M

,

Mous

R

,

Clausen

MR

, et al.

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

.

Lancet

.

2021

;

398

(

10306

):

1157

-

1169

.

71.

Robinson

HR

,

Qi

J

,

Cook

EM

, et al.

A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era

.

Blood

.

2018

;

132

(

5

):

521

-

532

.

72.

Kater

AP

,

Ye

JC

,

Sandoval-Sus

J

, et al.

Subcutaneous epcoritamab in patients with Richter's syndrome: early results from phase 1b/2 trial (EPCORE CLL-1)

.

Blood

.

2022

;

140

(

suppl 1

):

850

-

851

.

73.

Kater

A

,

Eradat

H

,

Niemann

C

, et al. Epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 1b/2 EPCORE CLL-1 Trial Expansion Cohort - Abstract 1546171. Paper presented at: 2023 International Workshop on CLL.

6-9 October 2023

. Boston, MA.

74.

Mhibik

M

,

Gaglione

EM

,

Eik

D

, et al.

Cytotoxicity of the CD3xCD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting

.

Blood Adv

.

2023

;

7

(

15

):

4089

-

4101

.

75.

Melenhorst

JJ

,

Chen

GM

,

Wang

M

, et al.

Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells

.

Nature

.

2022

;

602

(

7897

):

503

-

509

.

76.

Todorovic

Z

,

Todorovic

D

,

Markovic

V

, et al.

CAR T cell therapy for chronic lymphocytic leukemia: successes and shortcomings

.

Curr Oncol

.

2022

;

29

(

5

):

3647

-

3657

.

77.

Funk

CR

,

Wang

S

,

Chen

KZ

, et al.

PI3Kdelta/gamma inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity

.

Blood

.

2022

;

139

(

4

):

523

-

537

.

78.

Gauthier

J

,

Hirayama

AV

,

Purushe

J

, et al.

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

.

Blood

.

2020

;

135

(

19

):

1650

-

1660

.

79.

Gill

S

,

Vides

V

,

Frey

NV

, et al.

Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia

.

Blood Adv

.

2022

;

6

(

21

):

5774

-

5785

.

80.

Liu

M

,

Deng

H

,

Mu

J

, et al.

Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma

.

Cancer Sci

.

2021

;

112

(

7

):

2642

-

2651

.

81.

Fraietta

JA

,

Beckwith

KA

,

Patel

PR

, et al.

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

.

Blood

.

2016

;

127

(

9

):

1117

-

1127

.

82.

Zhou

J

,

Tang

Z

,

Gao

S

,

Li

C

,

Feng

Y

,

Zhou

X

.

Tumor-associated macrophages: recent insights and therapies

.

Front Oncol

.

2020

;

10

:

188

.

83.

Fiorcari

S

,

Maffei

R

,

Atene

CG

,

Potenza

L

,

Luppi

M

,

Marasca

R

.

Nurse-like cells and chronic lymphocytic leukemia B cells: a mutualistic crosstalk inside tissue microenvironments

.

Cells

.

2021

;

10

(

2

):

217

.

84.

Burger

JA

,

Tsukada

N

,

Burger

M

,

Zvaifler

NJ

,

Dell'Aquila

M

,

Kipps

TJ

.

Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell–derived factor-1

.

Blood

.

2000

;

96

(

8

):

2655

-

2663

.

85.

Tsukada

N

,

Burger

JA

,

Zvaifler

NJ

,

Kipps

TJ

.

Distinctive features of “nurselike” cells that differentiate in the context of chronic lymphocytic leukemia

.

Blood

.

2002

;

99

(

3

):

1030

-

1037

.

86.

Nishio

M

,

Endo

T

,

Tsukada

N

, et al.

Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1α

.

Blood

.

2005

;

106

(

3

):

1012

-

1020

.

87.

Boissard

F

,

Laurent

C

,

Ramsay

AG

, et al.

Nurse-like cells impact on disease progression in chronic lymphocytic leukemia

.

Blood Cancer J

.

2016

;

6

(

1

):

e381

.

88.

Jia

L

,

Clear

A

,

Liu

F-T

, et al.

Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia

.

Blood

.

2014

;

123

(

11

):

1709

-

1719

.

89.

Hanna

BS

,

McClanahan

F

,

Yazdanparast

H

, et al.

Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo

.

Leukemia

.

2016

;

30

(

3

):

570

-

579

.

90.

Galletti

G

,

Scielzo

C

,

Barbaglio

F

, et al.

Targeting macrophages sensitizes chronic lymphocytic leukemia to apoptosis and inhibits disease progression

.

Cell Rep

.

2016

;

14

(

7

):

1748

-

1760

.

91.

Ravichandran

KS

.

Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums

.

J Exp Med

.

2010

;

207

(

9

):

1807

-

1817

.

92.

Montalvao

F

,

Garcia

Z

,

Celli

S

, et al.

The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging

.

J Clin Invest

.

2013

;

123

(

12

):

5098

-

5103

.

93.

Gul

N

,

Babes

L

,

Siegmund

K

, et al.

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

.

J Clin Invest

.

2014

;

124

(

2

):

812

-

823

.

94.

Chao

MP

,

Alizadeh

AA

,

Tang

C

, et al.

Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma

.

Cell

.

2010

;

142

(

5

):

699

-

713

.

95.

Willingham

SB

,

Volkmer

JP

,

Gentles

AJ

, et al.

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

.

Proc Natl Acad Sci U S A

.

2012

;

109

(

17

):

6662

-

6667

.

96.

Ansell

SM

,

Maris

MB

,

Lesokhin

AM

, et al.

Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies

.

Clin Cancer Res

.

2021

;

27

(

8

):

2190

-

2199

.

97.

Daver

NG

,

Vyas

P

,

Kambhampati

S

, et al.

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: phase 1b results

.

J Clin Oncol

.

2022

;

40

(

16 suppl

):

7020

.

98.

Chauchet

X

,

Cons

L

,

Chatel

L

, et al.

CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model

.

Exp Hematol Oncol

.

2022

;

11

(

1

):

26

.

99.

Valentin

R

,

Peluso

MO

,

Lehmberg

TZ

, et al.

The fully human anti-CD47 antibody SRF231 has dual-mechanism antitumor activity against chronic lymphocytic leukemia (CLL) cells and increases the activity of both rituximab and venetoclax

.

Blood

.

2018

;

132

(

suppl 1

):

4393

.

100.

Zeller

T

,

Lutz

S

,

Munnich

IA

, et al.

Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages

.

Front Immunol

.

2022

;

13

:

929339

.

101.

Hartley

GP

,

Chow

L

,

Ammons

DT

,

Wheat

WH

,

Dow

SW

.

Programmed cell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation

.

Cancer Immunol Res

.

2018

;

6

(

10

):

1260

-

1273

.

102.

Wang

J

,

Sun

Y

,

Chu

Q

, et al.

Phase I study of IBI322 (anti-CD47/PD-L1 bispecific antibody) monotherapy therapy in patients with advanced solid tumors in China

. Abstract CT513.

Cancer Res

.

2022

;

82

(

12 suppl

).

103.

Wang

Y

,

Ni

H

,

Zhou

S

, et al.

Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity

.

Cancer Immunol Immunother

.

2021

;

70

(

2

):

365

-

376

.

104.

Sportoletti

P

,

De Falco

F

,

Del Papa

B

, et al.

NK cells in chronic lymphocytic leukemia and their therapeutic implications

.

Int J Mol Sci

.

2021

;

22

(

13

):

6665

.

105.

Parry

HM

,

Stevens

T

,

Oldreive

C

, et al.

NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma

.

Oncotarget

.

2016

;

7

(

42

):

68513

-

68526

.

106.

Lotz

M

,

Ranheim

E

,

Kipps

TJ

.

Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells

.

J Exp Med

.

1994

;

179

(

3

):

999

-

1004

.

107.

Wagner

B

,

da Silva Nardi

F

,

Schramm

S

, et al.

HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemia

.

Cancer

.

2017

;

123

(

5

):

814

-

823

.

108.

Maki

G

,

Hayes

GM

,

Naji

A

, et al.

NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G

.

Leukemia

.

2008

;

22

(

5

):

998

-

1006

.

109.

McWilliams

EM

,

Mele

JM

,

Cheney

C

, et al.

Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia

.

Oncoimmunology

.

2016

;

5

(

10

):

e1226720

.

110.

Hofland

T

,

Endstra

S

,

Gomes

CKP

, et al.

Natural killer cell hypo-responsiveness in chronic lymphocytic leukemia can be circumvented in vitro by adequate activating signaling

.

Hemasphere

.

2019

;

3

(

6

):

e308

.

111.

Deuse

T

,

Hu

X

,

Agbor-Enoh

S

, et al.

The SIRPα–CD47 immune checkpoint in NK cells

.

J Exp Med

.

2021

;

218

(

3

):

e20200839

.

112.

Xie

G

,

Dong

H

,

Liang

Y

,

Ham

JD

,

Rizwan

R

,

Chen

J

.

CAR-NK cells: a promising cellular immunotherapy for cancer

.

EBioMedicine

.

2020

;

59

:

102975

.

113.

Liu

E

,

Marin

D

,

Banerjee

P

, et al.

Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors

.

N Engl J Med

.

2020

;

382

(

6

):

545

-

553

.

114.

Bachanova

V

,

Ghobadi

A

,

Patel

K

, et al.

Safety and efficacy of FT596, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy in relapsed/refractory B-cell lymphoma

.

Blood

.

2021

;

138

(

suppl 1

):

823

.

115.

Pinto

S

,

Pahl

J

,

Schottelius

A

,

Carter

PJ

,

Koch

J

.

Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers

.

Trends Immunol

.

2022

;

43

(

11

):

932

-

946

.

116.

Gleason

MK

,

Verneris

MR

,

Todhunter

DA

, et al.

Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production

.

Mol Cancer Ther

.

2012

;

11

(

12

):

2674

-

2684

.

117.

Dubois

N

,

Crompot

E

,

Meuleman

N

,

Bron

D

,

Lagneaux

L

,

Stamatopoulos

B

.

Importance of crosstalk between chronic lymphocytic leukemia cells and the stromal microenvironment: direct contact, soluble factors, and extracellular vesicles

.

Front Oncol

.

2020

;

10

:

1422

.

118.

Heinig

K

,

Gatjen

M

,

Grau

M

, et al.

Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B-cell activation and proliferation

.

Cancer Discov

.

2014

;

4

(

12

):

1448

-

1465

.

119.

Lutzny

G

,

Kocher

T

,

Schmidt-Supprian

M

, et al.

Protein kinase c-beta-dependent activation of NF-kappaB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo

.

Cancer Cell

.

2013

;

23

(

1

):

77

-

92

.

120.

Paggetti

J

,

Haderk

F

,

Seiffert

M

, et al.

Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts

.

Blood

.

2015

;

126

(

9

):

1106

-

1117

.

121.

Böttcher

M

,

Bruns

H

,

Völkl

S

, et al.

Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis

.

J Immunother Cancer

.

2021

;

9

(

4

):

e001889

.

122.

vom Stein

AF

,

Rebollido-Rios

R

,

Lukas

A

, et al.

LYN kinase programs stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1

.

Nat Commun

.

2023

;

14

(

1

):

1330

.

123.

Sakemura

R

,

Hefazi

M

,

Siegler

EL

, et al.

Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma

.

Blood

.

2022

;

139

(

26

):

3708

-

3721

.

124.

Tauriello

DVF

,

Palomo-Ponce

S

,

Stork

D

, et al.

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

.

Nature

.

2018

;

554

(

7693

):

538

-

543

.

125.

Metropulos

AE

,

Munshi

HG

,

Principe

DR

.

The difficulty in translating the preclinical success of combined TGFbeta and immune checkpoint inhibition to clinical trial

.

EBioMedicine

.

2022

;

86

:

104380

.

126.

Ten Hacken

E

,

Burger

JA

.

Microenvironment interactions and B-cell receptor signaling in chronic lymphocytic leukemia: implications for disease pathogenesis and treatment

.

Biochim Biophys Acta

.

2016

;

1863

(

3

):

401

-

413

.

127.

Parvin

S

,

Aryal

A

,

Yin

S

, et al.

Targeting conditioned media dependencies and FLT-3 in chronic lymphocytic leukemia

.

Blood Adv

.

2023

;

7

(

19

):

5877

-

5889

.

128.

McWilliams

EM

,

Lucas

CR

,

Chen

T

, et al.

Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib

.

Blood Adv

.

2019

;

3

(

3

):

447

-

460

.

129.

Andritsos

LA

,

Byrd

JC

,

Cheverton

P

, et al.

A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia

.

Leuk Lymphoma

.

2019

;

60

(

14

):

3461

-

3469

.

130.

Tandler

C

,

Schmidt

M

,

Heitmann

JS

, et al.

Neutralization of B-cell activating factor (BAFF) by belimumab reinforces small molecule inhibitor treatment in chronic lymphocytic leukemia

.

Cancers (Basel)

.

2020

;

12

(

10

):

2725

.

131.

Svanberg

R

,

Janum

S

,

Patten

PEM

,

Ramsay

AG

,

Niemann

CU

.

Targeting the tumor microenvironment in chronic lymphocytic leukemia

.

Haematologica

.

2021

;

106

(

9

):

2312

-

2324

.

132.

Nguyen

P-H

,

Niesen

E

,

Hallek

M

.

New roles for B cell receptor associated kinases: when the B cell is not the target

.

Leukemia

.

2019

;

33

(

3

):

576

-

587

.

133.

Dubovsky

JA

,

Beckwith

KA

,

Natarajan

G

, et al.

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

.

Blood

.

2013

;

122

(

15

):

2539

-

2549

.

134.

Palma

M

,

Mulder

TA

,

Osterborg

A

.

BTK inhibitors in chronic lymphocytic leukemia: biological activity and immune effects

.

Front Immunol

.

2021

;

12

:

686768

.

135.

Mhibik

M

,

Wiestner

A

,

Sun

C

.

Harnessing the effects of BTKi on T cells for effective immunotherapy against CLL

.

Int J Mol Sci

.

2019

;

21

(

1

):

68

.

136.

Zou

Y-X

,

Zhu

H-Y

,

Li

X-T

, et al.

The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

.

Hematol Oncol

.

2019

;

37

(

4

):

392

-

400

.

137.

de Weerdt

I

,

Hofland

T

,

Lameris

R

, et al.

Improving CLL Vgamma9Vdelta2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib

.

Blood

.

2018

;

132

(

21

):

2260

-

2272

.

138.

Mhibik

M

,

Gaglione

EM

,

Eik

D

, et al.

BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL

.

Blood

.

2021

;

138

(

19

):

1843

-

1854

.

139.

Kaneda

MM

,

Messer

KS

,

Ralainirina

N

, et al.

PI3Kγ is a molecular switch that controls immune suppression

.

Nature

.

2016

;

539

(

7629

):

437

-

442

.

140.

De Henau

O

,

Rausch

M

,

Winkler

D

, et al.

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

.

Nature

.

2016

;

539

(

7629

):

443

-

447

.

141.

Isoyama

S

,

Mori

S

,

Sugiyama

D

, et al.

Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal

.

J Immunother Cancer

.

2021

;

9

(

8

):

e002279

.

142.

Contri

A

,

Brunati

AM

,

Trentin

L

, et al.

Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis

.

J Clin Invest

.

2005

;

115

(

2

):

369

-

378

.

143.

Kater

AP

,

Spiering

M

,

Liu

RD

, et al.

Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study

.

Leuk Res

.

2014

;

38

(

1

):

34

-

41

.

144.

Amrein

PC

,

Attar

EC

,

Takvorian

T

, et al.

Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia

.

Clin Cancer Res

.

2011

;

17

(

9

):

2977

-

2986

.

145.

Kadia

T

,

Delioukina

ML

,

Kantarjian

HM

, et al.

A pilot phase II study of the Lyn kinase inhibitor bafetinib in patients with relapsed or refractory B cell chronic lymphocytic leukemia

.

Blood

.

2011

;

118

(

21

):

2858

.

146.

Nguyen

PH

,

Fedorchenko

O

,

Rosen

N

, et al.

LYN kinase in the tumor microenvironment is essential for the progression of chronic lymphocytic leukemia

.

Cancer Cell

.

2016

;

30

(

4

):

610

-

622

.

147.

Thijssen

R

,

Slinger

E

,

Weller

K

, et al.

Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors

.

Haematologica

.

2015

;

100

(

8

):

e302

-

e306

.

148.

Hallaert

DY

,

Jaspers

A

,

van Noesel

CJ

,

van Oers

MH

,

Kater

AP

,

Eldering

E

.

c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches

.

Blood

.

2008

;

112

(

13

):

5141

-

5149

.

149.

Schade

AE

,

Schieven

GL

,

Townsend

R

, et al.

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation

.

Blood

.

2008

;

111

(

3

):

1366

-

1377

.

150.

Mestermann

K

,

Giavridis

T

,

Weber

J

, et al.

The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells

.

Sci Transl Med

.

2019

;

11

(

499

):

eaau5907

.

151.

Weber

EW

,

Lynn

RC

,

Sotillo

E

,

Lattin

J

,

Xu

P

,

Mackall

CL

.

Pharmacologic control of CAR-T cell function using dasatinib

.

Blood Adv

.

2019

;

3

(

5

):

711

-

717

.

152.

Baur

K

,

Heim

D

,

Beerlage

A

, et al.

Dasatinib for treatment of CAR T-cell therapy-related complications

.

J Immunother Cancer

.

2022

;

10

(

12

):

e005956

.

153.

Leclercq

G

,

Haegel

H

,

Schneider

A

, et al.

Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies

.

J Immunother Cancer

.

2021

;

9

(

7

):

e002582

.

154.

Redin

E

,

Garmendia

I

,

Lozano

T

, et al.

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

.

J Immunother Cancer

.

2021

;

9

(

3

):

e001496

.

155.

Philipp

N

,

Kazerani

M

,

Nicholls

A

, et al.

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

.

Blood

.

2022

;

140

(

10

):

1104

-

1118

.

156.

Weber

EW

,

Parker

KR

,

Sotillo

E

, et al.

Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling

.

Science

.

2021

;

372

(

6537

):

eaba1786

.

157.

Harrington

P

,

Dillon

R

,

Radia

D

, et al.

Differential inhibition of T cell receptor and STAT5 signalling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia

.

Haematologica

.

2023

;

108

(

6

):

1555

-

1566

.

158.

Hassold

N

,

Seystahl

K

,

Kempf

K

, et al.

Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib

.

Int J Cancer

.

2012

;

131

(

6

):

E916

-

E927

.

159.

Uchiyama

T

,

Sato

N

,

Narita

M

, et al.

Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study

.

Hematol Oncol

.

2013

;

31

(

3

):

156

-

163

.

160.

Rodriguez-Agustin

A

,

Casanova

V

,

Grau-Exposito

J

,

Sanchez-Palomino

S

,

Alcami

J

,

Climent

N

.

Immunomodulatory activity of the tyrosine kinase inhibitor dasatinib to elicit NK cytotoxicity against cancer, HIV infection and aging

.

Pharmaceutics

.

2023

;

15

(

3

):

917

.

161.

Kutsch

N

,

Pallasch

C

,

Tausch

E

, et al.

Efficacy and safety of the combination of tirabrutinib and entospletinib with or without obinutuzumab in relapsed chronic lymphocytic leukemia

.

Hemasphere

.

2022

;

6

(

4

):

e692

.

162.

Awan

FT

,

Thirman

MJ

,

Patel-Donnelly

D

, et al.

Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study

.

Leuk Lymphoma

.

2019

;

60

(

8

):

1972

-

1977

.

163.

Liu

T-M

,

Woyach

JA

,

Zhong

Y

, et al.

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

.

Blood

.

2015

;

126

(

1

):

61

-

68

.

164.

Paiva

C

,

Rowland

TA

,

Sreekantham

B

, et al.

SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia

.

Haematologica

.

2017

;

102

(

11

):

1890

-

1900

.

165.

Colado

A

,

Almejun

MB

,

Podaza

E

, et al.

The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients

.

Cancer Immunol Immunother

.

2017

;

66

(

4

):

461

-

473

.

166.

Elias

EE

,

Sarapura Martinez

VJ

,

Amondarain

M

, et al.

Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype

.

Cancer Immunol Immunother

.

2022

;

71

(

4

):

979

-

987

.

167.

Chanan-Khan

A

,

Miller

KC

,

Musial

L

, et al.

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

.

J Clin Oncol

.

2006

;

24

(

34

):

5343

-

5349

.

168.

Badoux

XC

,

Keating

MJ

,

Wen

S

, et al.

Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia

.

J Clin Oncol

.

2013

;

31

(

5

):

584

-

591

.

169.

Chavez

JC

,

Piris-Villaespesa

M

,

Dalia

S

, et al.

Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia

.

Leuk Res

.

2016

;

47

:

78

-

83

.

170.

Chanan-Khan

A

,

Porter

CW

.

Immunomodulating drugs for chronic lymphocytic leukaemia

.

Lancet Oncol

.

2006

;

7

(

6

):

480

-

488

.

171.

Fink

EC

,

Ebert

BL

.

The novel mechanism of lenalidomide activity

.

Blood

.

2015

;

126

(

21

):

2366

-

2369

.

172.

Fiorcari

S

,

Martinelli

S

,

Bulgarelli

J

, et al.

Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia

.

Haematologica

.

2015

;

100

(

2

):

253

-

262

.

173.

Maffei

R

,

Fiorcari

S

,

Martinelli

S

, et al.

Lenalidomide promotes a pro-inflammatory switch of nurse-like cells derived from chronic lymphocytic leukemia

.

Blood

.

2014

;

124

(

21

):

3286

.

174.

Schulz

A

,

Dürr

C

,

Zenz

T

, et al.

Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment

.

Blood

.

2013

;

121

(

13

):

2503

-

2511

.

175.

Ioannou

N

,

Jain

K

,

Ramsay

AG

.

Immunomodulatory drugs for the treatment of B cell malignancies

.

Int J Mol Sci

.

2021

;

22

(

16

):

8572

.

176.

Roider

T

,

Brinkmann

BJ

,

Kim

V

, et al.

An autologous culture model of nodal B-cell lymphoma identifies ex vivo determinants of response to bispecific antibodies

.

Blood Adv

.

2021

;

5

(

23

):

5060

-

5071

.

177.

Andritsos

LA

,

Johnson

AJ

,

Lozanski

G

, et al.

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia

.

J Clin Oncol

.

2008

;

26

(

15

):

2519

-

2525

.

178.

Saleem

K

,

Franz

J

,

Klem

ML

, et al.

Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis

.

Lancet Haematol

.

2022

;

9

(

12

):

e906

-

e918

.

179.

Li

B

,

Rampal

RK

,

Xiao

Z

.

Targeted therapies for myeloproliferative neoplasms

.

Biomark Res

.

2019

;

7

:

15

.

180.

Zeiser

R

,

von Bubnoff

N

,

Butler

J

, et al.

Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease

.

N Engl J Med

.

2020

;

382

(

19

):

1800

-

1810

.

181.

Jain

P

,

Keating

M

,

Renner

S

, et al.

Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial

.

Lancet Haematol

.

2017

;

4

(

2

):

e67

-

e74

.

182.

Blunt

MD

,

Koehrer

S

,

Dobson

RC

, et al.

The dual Syk/JAK inhibitor cerdulatinib antagonizes B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia

.

Clin Cancer Res

.

2017

;

23

(

9

):

2313

-

2324

.

183.

Spaner

DE

,

Luo

Y

,

Wang

G

,

Gallagher

J

,

Tsui

H

,

Shi

Y

.

Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: results of a phase II trial

.

Cancer Med

.

2021

;

10

(

24

):

8789

-

8798

.

184.

Ibrahim

S

,

Keating

M

,

Do

KA

, et al.

CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia

.

Blood

.

2001

;

98

(

1

):

181

-

186

.

185.

Malavasi

F

,

Deaglio

S

,

Damle

R

,

Cutrona

G

,

Ferrarini

M

,

Chiorazzi

N

.

CD38 and chronic lymphocytic leukemia: a decade later

.

Blood

.

2011

;

118

(

13

):

3470

-

3478

.

186.

Manna

A

,

Aulakh

S

,

Jani

P

, et al.

Targeting CD38 enhances the antileukemic activity of ibrutinib in chronic lymphocytic leukemia

.

Clin Cancer Res

.

2019

;

25

(

13

):

3974

-

3985

.

187.

Aurran-Schleinitz

T

,

Tomowiak

C

,

Roos-Weil

D

, et al.

Combined treatment with ibrutinib and anti-CD38 monoclonal antibody daratumumab in relapsed/refractory chronic lymphocytic leukemia with TP53 aberrations: results of the Filo Phase II Study IDA53

.

Blood

.

2022

;

140

(

suppl 1

):

7030

-

7031

.

188.

Matas-Cespedes

A

,

Vidal-Crespo

A

,

Rodriguez

V

, et al.

The human CD38 monoclonal antibody daratumumab shows antitumor activity and hampers leukemia-microenvironment interactions in chronic lymphocytic leukemia

.

Clin Cancer Res

.

2017

;

23

(

6

):

1493

-

1505

.

189.

Krejcik

J

,

Casneuf

T

,

Nijhof

IS

, et al.

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

.

Blood

.

2016

;

128

(

3

):

384

-

394

.

190.

Scholler

N

,

Perbost

R

,

Locke

FL

, et al.

Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma

.

Nat Med

.

2022

;

28

(

9

):

1872

-

1882

.

191.

Friedrich

MJ

,

Neri

P

,

Kehl

N

, et al.

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients

.

Cancer Cell

.

2023

;

41

(

4

):

711

-

725.e6

.

192.

Apollonio

B

,

Spada

F

,

Petrov

N

, et al.

Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma

.

J Clin Invest

.

2023

;

133

(

13

):

e166070

.

193.

Jain

MD

,

Zhao

H

,

Wang

X

, et al.

Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

.

Blood

.

2021

;

137

(

19

):

2621

-

2633

.

194.

van Bruggen

JAC

,

van der Windt

GJW

,

Hoogendoorn

M

,

Dubois

J

,

Kater

AP

,

Peters

FS

.

Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells

.

Blood Adv

.

2022

;

6

(

14

):

4185

-

4195

.

195.

Meermeier

EW

,

Welsh

SJ

,

Sharik

ME

, et al.

Tumor burden limits bispecific antibody efficacy through T-cell exhaustion averted by concurrent cytotoxic therapy

.

Blood Cancer Discov

.

2021

;

2

(

4

):

354

-

369

.

196.

Kater

AP

,

Levin

MD

,

Dubois

J

, et al.

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial

.

Lancet Oncol

.

2022

;

23

(

6

):

818

-

828

.

197.

Gruber

M

,

Bozic

I

,

Leshchiner

I

, et al.

Growth dynamics in naturally progressing chronic lymphocytic leukaemia

.

Nature

.

2019

;

570

(

7762

):

474

-

479

.

198.

Munir

T

,

Moreno

C

,

Owen

C

, et al.

Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in the GLOW study

.

J Clin Oncol

.

2023

;

41

(

21

):

3689

-

3699

.

199.

Yeh

P

,

Hunter

T

,

Sinha

D

, et al.

Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia

.

Nat Commun

.

2017

;

8

:

14756

.

200.

Furstenau

M

,

Weiss

J

,

Giza

A

, et al.

Circulating tumor DNA-based MRD assessment in patients with CLL treated with obinutuzumab, acalabrutinib, and venetoclax

.

Clin Cancer Res

.

2022

;

28

(

19

):

4203

-

4211

.

201.

Palma

M

,

Gentilcore

G

,

Heimersson

K

, et al.

T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers

.

Haematologica

.

2017

;

102

(

3

):

562

-

572

.

202.

Vardi

A

,

Vlachonikola

E

,

Papazoglou

D

, et al.

T-cell dynamics in chronic lymphocytic leukemia under different treatment modalities

.

Clin Cancer Res

.

2020

;

26

(

18

):

4958

-

4969

.

203.

Viel

S

,

Charrier

E

,

Marcais

A

, et al.

Monitoring NK cell activity in patients with hematological malignancies

.

Oncoimmunology

.

2013

;

2

(

9

):

e26011

.

204.

Gauthier

M

,

Durrieu

F

,

Martin

E

, et al.

Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia

.

BMC Cancer

.

2019

;

19

(

1

):

809

.

205.

Elston

L

,

Fegan

C

,

Hills

R

, et al.

Increased frequency of CD4+PD-1+HLA-DR+ T cells is associated with disease progression in CLL

.

Br J Haematol

.

2020

;

188

(

6

):

872

-

880

.

206.

Yin

Q

,

Sivina

M

,

Robins

H

, et al.

Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia

.

J Immunol

.

2017

;

198

(

4

):

1740

-

1747

.

207.

Kim

JM

,

Yi

E

,

Cho

H

, et al.

Assessment of NK cell activity based on NK cell-specific receptor synergy in peripheral blood mononuclear cells and whole blood

.

Int J Mol Sci

.

2020

;

21

(

21

):

8112

.